Regulus Therapeutics Inc.
RGLS
Price:
$8.16
Market Cap:
$564.95M
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headq...[Read more]
Industry
Biotechnology
IPO Date
2012-10-09
Stock Exchange
NASDAQ
Ticker
RGLS
PE Ratio
[-12.00]
ROE
[-57.53%]
Current Ratio
[16.31]
Dividend Yield
[0%]
Enterprise Value
[516.89M]
Dividend History
The Current Ratio as of November 2025 (TTM) for Regulus Therapeutics Inc. (RGLS) is 16.31
According to Regulus Therapeutics Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 16.31. This represents a change of 7.81% compared to the average of 15.12 of the last 4 quarters.
Regulus Therapeutics Inc. (RGLS) Historical Current Ratio (quarterly & annually)
How has RGLS Current Ratio performed in the past?
The mean historical Current Ratio of Regulus Therapeutics Inc. over the last ten years is 5.65. The current 16.31 Current Ratio has changed 28.77% with respect to the historical average. Over the past ten years (40 quarters), RGLS's Current Ratio was at its highest in in the June 2024 quarter at 19.06. The Current Ratio was at its lowest in in the March 2019 quarter at 0.71.
Average
5.65
Median
3.55
Minimum
0.72
Maximum
12.48
Regulus Therapeutics Inc. (RGLS) Current Ratio by Quarter and Year
Discovering the peaks and valleys of Regulus Therapeutics Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 293.41%
Maximum Annual Current Ratio = 12.48
Minimum Annual Increase = -69.70%
Minimum Annual Current Ratio = 0.72
| Year | Current Ratio | Change |
|---|---|---|
| 2024 | 10.98 | 231.54% |
| 2023 | 3.31 | -12.41% |
| 2022 | 3.78 | -69.70% |
| 2021 | 12.48 | 293.41% |
| 2020 | 3.17 | 69.57% |
| 2019 | 1.87 | 158.36% |
| 2018 | 0.72 | -64.63% |
| 2017 | 2.05 | -67.86% |
| 2016 | 6.37 | -45.74% |
| 2015 | 11.74 | -38.11% |
Regulus Therapeutics Inc. (RGLS) Average Current Ratio
How has RGLS Current Ratio performed in the past?
The current Current Ratio of Regulus Therapeutics Inc. (RGLS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
6.02
5-year avg
6.75
10-year avg
5.65
Regulus Therapeutics Inc. (RGLS) Current Ratio vs. Peers
How is RGLS’s Current Ratio compared to its peers?
Regulus Therapeutics Inc.’s Current Ratio is greater than Sage Therapeutics, Inc. (9.16), greater than Invivyd, Inc. (2.47), greater than Exscientia plc (4.54), greater than ARS Pharmaceuticals, Inc. (6.66), greater than Apollo Endosurgery, Inc. (2.35), greater than Niagen Bioscience Inc (3.88), greater than iTeos Therapeutics, Inc. (7.53), greater than Sinovac Biotech Ltd. (10.31), greater than Accolade, Inc. (2.63), greater than G1 Therapeutics, Inc. (3.87),
| Company | Current Ratio | Market cap |
|---|---|---|
| 9.16 | $544.94M | |
| 2.47 | $294.66M | |
| 4.54 | $633.18M | |
| 6.66 | $978.98M | |
| 2.35 | $579.72M | |
| 3.88 | $534.70M | |
| 7.53 | $448.68M | |
| 10.31 | $464.94M | |
| 2.63 | $575.59M | |
| 3.87 | $377.75M |
Build a custom stock screener for Regulus Therapeutics Inc. (RGLS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Regulus Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Regulus Therapeutics Inc. (RGLS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Regulus Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the Current Ratio?
How can you use the Current Ratio?
What is Regulus Therapeutics Inc.'s Current Ratio?
How is the Current Ratio calculated for Regulus Therapeutics Inc. (RGLS)?
What is the highest Current Ratio for Regulus Therapeutics Inc. (RGLS)?
What is the 3-year average Current Ratio for Regulus Therapeutics Inc. (RGLS)?
What is the 5-year average Current Ratio for Regulus Therapeutics Inc. (RGLS)?
How does the current Current Ratio for Regulus Therapeutics Inc. (RGLS) compare to its historical average?